Sector ratings Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 21/08/2026 BST			5-day change	1st Jan Change
14.30 ^USD	-3.25%		-7.74%	-8.80%

08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
MONTE ROSA THERAPEUTICS, INC.	1.22B	-	BB	-	-
LONZA GROUP AG	51.61B		AAA
REVOLUTION MEDICINES, INC.	44.89B	-	B	-	-
IQVIA HOLDINGS INC.	42.77B		AAA
BEONE MEDICINES AG	42.58B		-
CELLTRION, INC.	31.82B		A
MEDPACE HOLDINGS, INC.	17.33B		BBB
ASCENDIS PHARMA A/S	16.63B	-	-	-	-
EUROFINS SCIENTIFIC SE	14.76B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	14.09B		AA
ICON PUBLIC LIMITED COMPANY	13.29B		AAA
TEMPUS AI, INC.	13.12B		A		-
PHARMARON BEIJING CO., LTD.	12.06B		AA
BIO-TECHNE CORPORATION	11.34B		AA
ABIVAX	11.12B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	10.5B	-	B	-	-
APOGEE THERAPEUTICS, INC.	10.16B	-	B	-	-
PROTAGONIST THERAPEUTICS, INC.	9.99B		BB		-
KYMERA THERAPEUTICS, INC.	9.96B	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	9.93B	-	A	-	-
Average	19.46B		A
Weighted average by Cap.			A